Search

Your search keyword '"Pietro Salvago"' showing total 2 results
Start Over Author "Pietro Salvago" Publisher mdpi ag
2 results on '"Pietro Salvago"'

1. Risk Factors for Sensorineural Hearing Loss and Auditory Maturation in Children Admitted to Neonatal Intensive Care Units: Who Recovered?

Author

Pietro Salvago, Angelo Immordino, Fulvio Plescia, Marianna Mucia, Andrea Albera, and Francesco Martines

Subjects
NICU, sensorineural hearing loss, auditory maturation, Pediatrics, RJ1-570
Abstract

Background: Newborns admitted to neonatal intensive care units (NICUs) are at higher risk of developing sensorineural hearing loss (SNHL), which may improve over time. The aim of this study was to describe the prevalence of the main risk factors for SNHL in a NICU cohort, focusing on children who underwent auditory maturation. Methods: An observational study of 378 children admitted to NICUs, who were followed for at least 18 months, with periodic audiologic assessments. Results: Out of 378 patients, 338 had normal hearing and 40 were hearing-impaired; we found a higher percentage of extremely preterm (EPT) and extremely low-birthweight (ELBW) infants in SNHL children (p < 0.05). Seventeen infants presented auditory improvement, with a mean maturation time of 6.17 months. A significant difference emerged between patients with stable SNHL and those who improved only in the case of hyperbilirubinemia (p = 0.005). The initial hearing threshold was a predictor of auditory improvement and moderately correlated to the time of auditory maturation (p = 0.02). Conclusions: Our study supports the trend toward recognizing worse prognoses and slower maturation processes among NICU children who suffer from severe to profound SNHL. Caution must be taken when deciding on earlier cochlear implantation.

Published
2022
Full Text
View/download PDF

2. Efficacy and pharmacological appropriateness of cinnarizine and dimenhydrinate in the treatment of vertigo and related symptoms

Author

Fulvio Plescia, Francesco Martines, Giuseppe Messina, Francesco Dispenza, Emanuele Cannizzaro, Pietro Salvago, Plescia F., Salvago P., Dispenza F., Messina G., Cannizzaro E., and Martines F.

Subjects
Adult, Male, pharmacological treatment of vertigo, medicine.medical_specialty, Cinnarizine, Health, Toxicology and Mutagenesis, Disease, dimenhydrinate, Article, Cinnarizine, Dimenhydrinate, Dizziness, Pharmacological treatment of vertigo, Vertigo, Adult, Double-Blind Method, Drug Combinations, Female, Histamine H1 Antagonists, Humans, Male, Middle Aged, Cinnarizine, Dimenhydrinate, vertigo, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Double-Blind Method, Vertigo, Internal medicine, medicine, otorhinolaryngologic diseases, Humans, 030212 general & internal medicine, cinnarizine, 030223 otorhinolaryngology, dizziness, Balance (ability), biology, business.industry, Public Health, Environmental and Occupational Health, Middle Aged, biology.organism_classification, Dimenhydrinate, Drug Combinations, Tolerability, Concomitant, Histamine H1 Antagonists, Medicine, Female, business, medicine.drug
Abstract

Vertigo is not itself a disease, but rather a symptom of various syndromes and disorders that jeopardize balance function, which is essential for daily activities. It is an abnormal sensation of motion that usually occurs in the absence of motion, or when a motion is sensed inaccurately. Due to the complexity of the etiopathogenesis of vertigo, many pharmacological treatments have been tested for efficacy on vertigo. Among these drugs, cinnarizine, usually given together with dimenhydrinate, appears to be the first-line pharmacotherapy for the management of vertigo and inner ear disorders. Based on these considerations, the present non-interventional study aimed to investigate the clinical efficacy and tolerability of a fixed combination of cinnarizine (20 mg) and dimenhydrinate (40 mg) in patients suffering from vertigo-related symptoms. To this end, we enrolled 120 adults—70 males, and 50 females—with an average age of 64 years. Before beginning pharmacological treatment, all patients were screened for the intensity of vertigo, dizziness, and concomitant symptoms through the Visual Scale of Dizziness Disorders and Dizziness Handicap Inventory scales. At the end of the anamnestic evaluation, patients received the fixed-dose combination of cinnarizine (20 mg) plus dimenhydrinate (40 mg) 3 times daily, for 60 days. The results of this study provide further insight regarding the efficacy of the fixed combination when used to reduce symptoms of vestibular vertigo of central and/or peripheral origin, after both the 15- and 60-day therapies. Independent of the type of vertigo, the fixed combination was able to reduce dizziness- and vertigo-associated symptoms in more than 75% of all patients treated, starting from 15 days of therapy, and improving 60 days after starting the therapy. Interestingly, we also found differences between male and female patients in the framework of the pharmacological effects of therapy. This study provides further details concerning the therapeutic efficacy of the fixed combination of cinnarizine and dimenhydrinate, and also focuses attention on the possibility that these drugs could act in a gender-specific manner, paving the way for further research.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results